Fu­ji­film com­pletes ac­qui­si­tion of Atara's cell ther­a­py man­u­fac­tur­ing site near Los An­ge­les

In Jan­u­ary, Atara Bio­ther­a­peu­tics inked a deal with Fu­ji­film Diosynth to ex­change its Cal­i­for­nia man­u­fac­tur­ing site for $100 mil­lion up­front, and a long-term li­cens­ing deal for its al­lo­gene­ic T-cell ther­a­py plat­form for pa­tients with can­cer and au­toim­mune dis­ease. Mon­day, the biotech an­nounced that the deal has now been com­plet­ed, and the part­ner­ship has be­gun.

Fu­ji­film Diosynth will now give Atara ac­cess to the flex ca­pac­i­ty to man­u­fac­ture both clin­i­cal and com­mer­cial stage ther­a­pies for tab-cel, its off-the-shelf, al­lo­gene­ic T-cell im­munother­a­py in de­vel­op­ment for the treat­ment of Ep­stein-Barr virus pos­i­tive post-trans­plant lym­pho­pro­lif­er­a­tive dis­ease, its can­di­date ATA188 for mul­ti­ple scle­ro­sis, and al­lo­gene­ic CAR-T ther­a­pies ATA3271 and ATA3219.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER